PL362252A1 - Teraputyczna kombinacja amlodypiny i benazeprilu - Google Patents

Teraputyczna kombinacja amlodypiny i benazeprilu

Info

Publication number
PL362252A1
PL362252A1 PL00362252A PL36225200A PL362252A1 PL 362252 A1 PL362252 A1 PL 362252A1 PL 00362252 A PL00362252 A PL 00362252A PL 36225200 A PL36225200 A PL 36225200A PL 362252 A1 PL362252 A1 PL 362252A1
Authority
PL
Poland
Prior art keywords
amlodipine
pharmaceutically acceptable
benazepril
disease
corresponds
Prior art date
Application number
PL00362252A
Other languages
English (en)
Inventor
William Lionel Daley
Randy Lee Webb
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21742073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL362252(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL362252A1 publication Critical patent/PL362252A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL00362252A 2000-12-18 2000-12-18 Teraputyczna kombinacja amlodypiny i benazeprilu PL362252A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/034246 WO2002049645A1 (en) 2000-12-18 2000-12-18 Therapeutic combination of amlodipine and benazepril

Publications (1)

Publication Number Publication Date
PL362252A1 true PL362252A1 (pl) 2004-10-18

Family

ID=21742073

Family Applications (2)

Application Number Title Priority Date Filing Date
PL00362252A PL362252A1 (pl) 2000-12-18 2000-12-18 Teraputyczna kombinacja amlodypiny i benazeprilu
PL01360989A PL360989A1 (pl) 2000-12-18 2001-12-17 Terapeutyczna kombinacja amlodypiny i benzaperilu/benzaprilatu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL01360989A PL360989A1 (pl) 2000-12-18 2001-12-17 Terapeutyczna kombinacja amlodypiny i benzaperilu/benzaprilatu

Country Status (26)

Country Link
EP (3) EP1365761A1 (pl)
JP (3) JP2004516266A (pl)
KR (3) KR20040007420A (pl)
CN (2) CN1461218A (pl)
AT (1) ATE338549T1 (pl)
AU (4) AU2001225816B2 (pl)
BR (2) BR0017386A (pl)
CA (2) CA2432638A1 (pl)
CY (1) CY1106275T1 (pl)
CZ (2) CZ20031678A3 (pl)
DE (1) DE60122928T2 (pl)
DK (1) DK1345607T3 (pl)
EC (1) ECSP034658A (pl)
ES (1) ES2272565T3 (pl)
HU (2) HUP0302455A3 (pl)
IL (4) IL156136A0 (pl)
MX (2) MXPA03005462A (pl)
NO (2) NO20032766L (pl)
NZ (1) NZ526467A (pl)
PL (2) PL362252A1 (pl)
PT (1) PT1345607E (pl)
RU (1) RU2292206C2 (pl)
SI (1) SI1345607T1 (pl)
SK (2) SK7652003A3 (pl)
WO (2) WO2002049645A1 (pl)
ZA (1) ZA200304514B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04004844A (es) * 2001-11-23 2004-07-30 Solvay Pharm Gmbh Tratamiento de hipertonia durante la fase aguda de un accidente cerebrobascular.
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
CA2522971A1 (en) 2003-04-25 2004-11-11 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
CN101137367A (zh) * 2003-10-20 2008-03-05 诺瓦提斯公司 用于降低心血管发病率的贝那普利和氨氯地平
WO2005074927A1 (en) * 2004-02-09 2005-08-18 Novartis Ag Therapeutic combination of amlodipine and benazepril/ benazeprilat for the treatment of hypertension
WO2005079772A2 (en) * 2004-02-18 2005-09-01 Sepracor Inc. Combination of (s)-amlodipine and an ace inhibitor, and methods for reducing hypertension
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
US20080268049A1 (en) * 2005-02-11 2008-10-30 Dhaliwal Mona Stable Solid Dosage Forms of Amlodipine and Benazepril
WO2006092732A2 (en) * 2005-03-04 2006-09-08 Aurobindo Pharma Ltd Stable solid dosage form of antihypertensive agent
NZ561486A (en) 2005-03-15 2011-03-31 Lupin Ltd Pharmaceutical compositions of amlodipine and benazepril
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
DE602005005706T2 (de) * 2005-09-28 2009-04-16 Teva Pharmaceutical Industries Ltd. Stabile Arzneimittelkombinationen von Amlodipinbesylat und Benazeprilhydrochlorid
AU2005336956A1 (en) * 2005-09-28 2007-04-12 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
IT1398168B1 (it) * 2010-02-16 2013-02-14 Chiesi Farma Spa Uso di ingredienti attivi in combinazione per il trattamento delle complicanze del diabete.
EA027787B1 (ru) 2010-06-23 2017-09-29 Крка, Товарна Здравил, Д.Д., Ново Место Пероральные лекарственные формы, содержащие лерканидипин и эналаприл и их фармацевтически приемлемые соли
CN102389431A (zh) * 2011-09-28 2012-03-28 济南龙华医药技术有限公司 一种含有盐酸贝尼地平和盐酸贝那普利的复方制剂及其应用
HUE035830T2 (en) * 2011-12-21 2018-05-28 Elanco Tiergesundheit Ag New combination
HUE060093T2 (hu) 2012-03-15 2023-01-28 Boehringer Ingelheim Vetmedica Gmbh Gyógyszerészeti tablettakészítmény az állatgyógyászati ágazat számára, eljárás annak elõállítására és annak alkalmazása
JP2015529206A (ja) * 2012-08-25 2015-10-05 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｇａｐｄｈカスケードインヒビター化合物ならびに使用の方法および精神病を含むストレス誘導障害の処置
HUE054186T2 (hu) 2013-07-19 2021-08-30 Boehringer Ingelheim Vetmedica Gmbh Éterezett ciklodextrin-származékokat tartalmazó, tartósított, folyékony, vizes gyógyászati készítmény
ES2883448T3 (es) 2013-12-04 2021-12-07 Boehringer Ingelheim Vetmedica Gmbh Composiciones farmacéuticas mejoradas de pimobendán
CN108778334A (zh) * 2016-03-24 2018-11-09 第三共株式会社 用于治疗肾脏疾病的药物
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
DK3541807T3 (da) 2016-11-16 2021-12-06 H Lundbeck As Krystallinsk form af en magl-inhibitor
KR20190085046A (ko) 2016-11-16 2019-07-17 어바이드 테라퓨틱스, 인크. 약학 제제

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162802A (en) * 1992-03-10 2000-12-19 Papa; Joseph Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
WO1996028185A2 (en) * 1995-03-16 1996-09-19 Pfizer Inc. Composition containing amlodipine, or a salt, or felodipine and an ace inhibitor
CZ313897A3 (cs) * 1995-04-07 1998-01-14 Novartis Ag Farmaceutické kompozice obsahující benazepril nebo benazeprilát a valsartan
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin

Also Published As

Publication number Publication date
DE60122928D1 (de) 2006-10-19
MXPA03005463A (es) 2003-09-25
HUP0302456A3 (en) 2004-05-28
ATE338549T1 (de) 2006-09-15
NO20032766D0 (no) 2003-06-17
EP1345607A1 (en) 2003-09-24
PT1345607E (pt) 2007-01-31
IL190802A0 (en) 2008-11-03
EP1674099A1 (en) 2006-06-28
ECSP034658A (es) 2003-07-25
JP2004519440A (ja) 2004-07-02
PL360989A1 (pl) 2004-09-20
ES2272565T3 (es) 2007-05-01
AU2581601A (en) 2002-07-01
BR0116228A (pt) 2003-12-30
CZ20031677A3 (cs) 2003-10-15
NO20032766L (no) 2003-08-14
NZ526467A (en) 2005-04-29
BR0017386A (pt) 2004-01-13
NO20032765L (no) 2003-08-14
SI1345607T1 (sl) 2007-02-28
AU2002232620B2 (en) 2005-11-03
IL190801A0 (en) 2008-11-03
CN1481241A (zh) 2004-03-10
SK7642003A3 (en) 2003-11-04
CN1461218A (zh) 2003-12-10
IL156136A0 (en) 2003-12-23
HUP0302456A2 (hu) 2003-11-28
JP2010043111A (ja) 2010-02-25
EP1345607B1 (en) 2006-09-06
JP2004516266A (ja) 2004-06-03
CA2432638A1 (en) 2002-06-27
CZ301424B6 (cs) 2010-02-24
CA2432282A1 (en) 2002-06-27
DK1345607T3 (da) 2006-12-27
WO2002049645A1 (en) 2002-06-27
RU2292206C2 (ru) 2007-01-27
SK7652003A3 (en) 2003-12-02
AU3262002A (en) 2002-07-01
HUP0302455A2 (hu) 2003-11-28
CY1106275T1 (el) 2011-10-12
CZ20031678A3 (cs) 2003-10-15
WO2002049646A1 (en) 2002-06-27
ZA200304514B (en) 2004-05-10
HK1059566A1 (en) 2004-07-09
KR20040007420A (ko) 2004-01-24
DE60122928T2 (de) 2007-09-06
AU2002232620B9 (en) 2005-11-24
IL156267A0 (en) 2004-01-04
KR20090033914A (ko) 2009-04-06
NO20032765D0 (no) 2003-06-17
AU2001225816B2 (en) 2005-10-13
HUP0302455A3 (en) 2005-05-30
MXPA03005462A (es) 2003-09-25
EP1365761A1 (en) 2003-12-03
RU2003121019A (ru) 2005-01-20
KR20030061840A (ko) 2003-07-22

Similar Documents

Publication Publication Date Title
IL190801A0 (en) Therapeutic combination of amlodipine and benazepril/benazeprilat
RU2243768C2 (ru) Гипотензивная комбинация валсартана и блокатора кальциевых каналов
RU2334513C2 (ru) Фармацевтические композиции, включающие валсартан и ингибиторы нейтральной эндопептидазы (nep)
WO2003041725A3 (de) REGULATION DER cGMP-SPEZIFISCHEN PHOSPHODIESTERASE 9A
KR101389879B1 (ko) 심부전의 치료에서의 동결절 Ｉｆ 전류 억제제 및 안지오텐신-전환 효소 억제제의 회합물의 용도
KR20090047424A (ko) 굴심방 결절 Ｉｆ 전류 억제제와 앤지오텐신 전환 효소 억제제의 회합체, 및 이를 함유한 약제 조성물
JP2003522768A5 (pl)
SG153644A1 (en) Therapeutic combination of amlodipine and benazepril
KR100907584B1 (ko) 굴심방 결절 Ｉｆ 전류 억제제 및 칼슘채널억제제의 회합체 및 이를 함유하는 약제 조성물
RU2003121016A (ru) Терапевтическая комбинация амлодипина и беназеприла
DK0554107T3 (da) Substituerede triazoler som angiotensin II inhibitorer
HK1106444B (en) New association of a sinus node if current inhibitor and an angiotensin-converting enzyme inhibitor, and pharmaceutical compositions containing it

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)